Cyclic adenosine 5′-diphosphate ribose (cADPR) is an emerging Ca 2+ -mobilising second messenger. cADPR analogues have been generated as chemical biology tools via both chemo-enzymatic and total synthetic routes. Both routes rely on the cyclisation of a linear precursor to close an 18-membered macrocyclic ring. We show here that, after cyclisation, there are two possible macrocyclic product conformers that may be formed, depending on whether cyclisation occurs to the "right" or the "left" of the adenine base (as viewed along the H-8 → C-8 base axis). Molecular modelling demonstrates that these two conformers are distinct and cannot interconvert. The two conformers would present a different spatial layout of binding partners to the cADPR receptor/binding site. For chemoenzymatically generated analogues Aplysia californica ADP-ribosyl cyclase acts as a template to generate solely the "right-handed" conformer and this corresponds to that of the natural messenger, as originally explored using crystallography. However, for a total synthetic analogue it is theoretically possible to generate either product, or a mixture, from a given linear precursor. Cyclisation on either face of the adenine base is broadly illustrated by the first chemical synthesis of the two enantiomers of a "southern" ribose-simplified cIDPR analogue 8-Br-N9-butyl-cIDPR, a cADPR analogue containing only one chiral sugar in the "northern" ribose, i.e. 8-Br-D-and its mirror image 8-Br-L-N9-butyl-cIDPR. By replacing the D-ribose with the unnatural L-ribose sugar, cyclisation of the linear precursor with pyrophosphate closure generates a cyclised product spectroscopically identical, but displaying equal and opposite specific rotation. These findings have implications for cADPR analogue design, synthesis and activity.
Cyclic adenosine 5′-diphosphate ribose (cADPR, 1) is a cyclic dinucleotide that is produced enzymatically from nicotinamide adenine dinucleotide (NAD + , 2) by ADP-ribosyl cyclases CD38 and CD157 in humans ( Fig. 1) 1 . It mobilizes intracellular Ca 2+ that in turn controls a diverse range of highly regulated cellular processes 2, 3 . cADPR itself is readily hydrolysed at the labile N1 linkage in both neutral aqueous solution and under physiological conditions, generating another second messenger, ADPR, 3 4, 5 .
The physiological receptor for cADPR is the ryanodine receptor, although the actual Ca 2+ release mechanism is still somewhat controversial and auxiliary cADPR binding proteins have been invoked. Recently, the apparently definitive auxiliary protein GADPH as the long-sought-after target was proposed 6 . Synthesis of stable cADPR analogues is important for studies attempting to unravel mechanistic aspects behind the cADPR/Ca 2+ signalling system. The structure-activity relationship of cADPR-induced Ca 2+ release revealed by cADPR analogues is still evolving and presents a complex picture. Single atomic substitutions can completely abolish activity or generate potent antagonists, and analogue activity also varies between different organisms 7 . Despite the large number of analogues prepared and the amount of pharmacological data, very little is known about whether or how these small alterations affect cADPR conformation. We previously studied the role of the "southern" ribose conformation in activity at the sea urchin cADPR receptor 7 , and a recent detailed NMR study has analysed both ribose conformations in four cADPR analogues that were prepared via the chemo-enzymatic route 8 . What now seems clear is that total synthetic routes to analogues, although labour intensive, will likely yield the most diverse structural modifications. Here, we consider an as-yet-unexplored more fundamental conformational difference that could lead to different biological activity for cADPR analogues prepared via total synthetic routes.
The mechanism by which CD38 cyclises NAD + to form cADPR has been studied in detail by crystallography [9] [10] [11] . Chemo-enzymatic routes to cADPR analogues rely on recognition of the relevant NAD + analogue by Aplysia californica ADP-ribosyl cyclase. Unlike CD38, the Aplysia californica cyclase displays predominantly cyclase activity and is easily purified 12 . N1-cIDPR (6) was first prepared by this route and is more chemically and biologically stable than cADPR, due to a 6-NH 2 → 6 = O substitution removing the partial positive charge from N1 (Fig. 2) 13 . N1-cIDPR acts as an agonist with equivalent potency to cADPR in permeabilised T-cells 13, 14 and 8-Br-cIDPR (5) was later shown to be the first membrane permeant agonist at the cADPR receptor 15 .
The main drawback of the chemo-enzymatic route is its reliance on recognition of an NAD + derivative as a substrate by Aplysia californica ADP-ribosyl cyclase and the correct orientation of that substrate in the active site 16 . For example, in such a synthesis of cIDPR (6) , an 8-bromo-NAD + analogue (8-Br-NHD + , 4) was required to generate N1-cIDPR (6) (without this 8-Br substitution, cyclisation proceeds to give the regioisomeric, fluorescent, but biologically-inactive N7-cIDPR) 13, 14, 17 . Total synthetic approaches to cADPR analogues are, however, not subject to the same limitations. In general, a linear precursor is cyclised by pyrophosphate formation, generating the macrocycle (Fig. 2 ). Pyrophosphate construction is frequently carried out by an intramolecular condensation reaction with an S-phenyl phosphorothioate in a modified Hata condensation 18 . A dilute solution of the linear precursor is treated with either I 2 or AgNO 3 and molecular sieves to promote intramolecular cyclisation. Total synthesis has facilitated inter alia the preparation of a number of "northern" ribose modified analogues [19] [20] [21] [22] that would likely be inaccessible via the chemo-enzymatic route. cADPR itself has not been prepared via a total synthetic route. Indeed, in most reported examples, a cADPR analogue is prepared only via one of the above routes. However, we recently developed an N1-ribosylation methodology to introduce, stereo-and regiospecifically, a protected ribose at the N1 of hypoxanthine, and reported the first total synthetic route to 8-Br-cIDPR (5) via cyclisation of 7 23 . The material prepared by total synthesis was spectroscopically identical to that obtained via the chemo-enzymatic route.
We report here the new idea that cADPR analogues may in principle cyclise to generate two different conformers, depending on the position of the pyrophosphate relative to the purine base. Modelling of cADPR and known analogues demonstrates that these conformers would be unable to interconvert and they would therefore exist as individual entities, with importantly potentially different biological activities. A total synthesis of the enantiomers of 8-Br-L-N9-butyl-cIDPR 11 and 8-Br-D-N9-butyl-cIDPR 9 (Fig. 8 ), a simplified cIDPR analogue with only one sugar moiety, illustrates in a simplified fashion to cIDPR the synthetic linear precursor cyclising through pyrophosphate formation on the two different faces of the adenine base. These two analogues represent, to the best of our knowledge, the first mirror image pair of cIDPR analogue enantiomers synthesised.
Results
The crystal structure of cADPR 24 and the co-crystal structures of cIDPR with CD38 11 and Aplysia californica ADP ribosyl cyclase 25 all show a cyclic ligand conformation where the phosphates are located to the "right" of the purine base, when the base is orientated arbitrarily so that H-8 → C-8 is in the foreground, with H-8 pointing towards the viewer and the 6-NH 2 or C=O respectively points upwards. Hereafter, this will be referred to as conformer A (Fig. 3 ). For easy comparison, all structures presented here are drawn with the purine base in this orientation. Inspecting the three-dimensional structure of cADPR, we questioned whether it would also be able to adopt a second conformation (that we have termed conformer B) where the phosphates sit to the left of the purine base ( Fig. 4a,b ). If two such conformers exist then, after closure of the macrocyclic ring, there are two possibilities. Either (a) conformers A and B can interconvert and may exist in equilibrium, or settle in the most energetically favoured conformer or (b) the two conformers cannot interconvert, making them distinct entities. This latter point is important, because if the two conformers are unable to interconvert a chemical cyclisation might generate either the "unwanted" conformer B, or a mixture of the two conformers. This is in contrast to the enzymatic cyclisation which, presumably, invariably generates only one conformer, A. Based upon our current knowledge of the SAR it is only conformer A that is likely to have biological activity. To model the situation, we built and minimised cADPR in both conformations, using the Schrödinger software. Conformer A is energetically favoured (151 Kcal mol −1 ) while conformer B has an energy of 161 Kcal mol −1 . Conformer A was put through three rounds of dynamics simulations at increasing temperatures to determine whether the phosphates might be able to pass to the other side of the adenine ring and generate conformer B (Supplementary Information Files 1-3).
Conversion from conformer A to B would require the diphosphate bridge to move 'under' the adenine 2-H or 'over' the 6-NH 2 and 8-H via simultaneous rotation around at least two bonds (those between the purine N1 and N9 and the ribose rings) as well as stretching of the bonds between the two ribose groups and distortion of the purine. At 298.15 K, only limited molecular movement is observed and there is no conversion. At 1298.15 K the molecular movement of the ribose rings and pyrophosphate is far more visible but the phosphates are still unable to move past the hydrogen atom in position 2 of the adenosine base. No conversion to conformer B is observed. At 4298.15 K the molecular movement is very vigorous and conversion of conformer A into B can apparently occur. This simulation was carried out five times, but in only one of them was conversion to conformer B observed. This suggests that a flip between conformers will occur only rarely under these extreme conditions, and presumably even more rarely (and likely not at all) under physiological conditions.
To probe whether other cADPR analogues would also have a fixed conformation, we examined conformer A of N1-cIDPR (6) 13 under the same conditions (1 ps at 1298.15 K, see Supplementary Information File 4) and found that the 6-NH 2 → 6 = O substitution did not alter the flexibility of the macrocycle. Similar substitutions in 8-Br-cADPR 26 , 6-Thio-cIDPR 27 and 8-NH 2 -cADPR 26 (see Supplementary Information Files 5-7) confirmed that these analogues are also trapped in conformer A. As might be expected, the larger 8-bromo and 8-amino substituents did not increase the possibility of conversion to conformer B. For completeness, we also modelled the corresponding conformer B of cADPR (1), N1-cIDPR (6), 8-Br-cADPR, 6-Thio-cIDPR, and 8-NH 2 -cADPR. These simulations confirmed the same inability to flip from conformer B to A (see Supplementary Information Files 8-12). Taken together, our results suggest that the conformer of cADPR (or cADPR analogue) that is generated during any cyclisation, chemical or enzymatic, is fixed with the phosphates trapped on one side of the purine base.
Analysis of cADPR conformers A and B suggests that the adenosine and ribose-ring hydrogens would have differing nuclear environments and thus that two distinct compounds would be visible by NMR spectroscopy ( Fig. 5 and Supplementary Information File 13). The "southern" ribose ring protons H-1′ and H-2′ would be affected by differing proximity to H-8 and the "northern" ribose H-1″ and H-2″ would be affected by their proximity to the N6-amino group. The changes in relative position of these groups would also likely be visible by comparison of nuclear Overhauser effect (NOE) spectra. We also measured the appropriate χ values for the sugar-base relationships of conformers A and B. Thus, in Fig. 5a the "southern" ribose-base χ angle O4′-C1′-N9-C4 is 46.8° and the northern ribose-base χ angle O4″-C1″-N1-C2 is 9.4°. In Fig. 5b the southern ribose-base χ angle O4′-C1′-N9-C4 is −6.2° and the northern ribose-base angle O4″-C1″-N1-C2 is 57.6°. All the angles fall within the range −90° to +90° and all sugar-base relationships are denoted as syn being thus syn/syn in each case. The observed χ angles are in good agreement with previous cADPR structural studies 8, 24 . Conformers A and B of any analogue also possess different 3D shapes and would be expected to interact differently with the cADPR binding site. This is an important consideration for studies where biological assays are used as a readout of cADPR analogue activity, as a seemingly inactive ligand generated by total synthesis could potentially instead be the undesired and inactive conformer.
Therefore, during the total synthesis of a cADPR analogue -the control (or lack thereof) over which conformer is formed during cyclisation by pyrophosphate formation could either lead to the generation of a mixture of both conformers or to the undesired conformer B. We postulated that generation of either conformer would be theoretically possible during total synthetic routes that employ a modified Hata condensation to generate the macrocycle (Fig. 6 ). Since using anhydrous pyridine as a solvent is critical to this reaction 18 , activation of the mono-thiophenyl phosphate by iodine in pyridine is likely to generate the pyridinium species 28 that is then attacked by the free phosphate to close the macrocycle. The presence of molecular sieves ensures anhydrous conditions where no activated phosphate is hydrolysed to the linear diphosphate 18 . During our total synthesis of 8-Br-cIDPR (5) 23 only one product was observed during modified Hata condensation. This product was identical by 1 H, 13 C, 31 P-NMR and HPLC to the 8-Br-cIDPR generated by the chemo-enzymatic route, suggesting it is conformer A. That only one of the two possible conformers is formed seems somewhat surprising given the flexibility of the linear precursor. Indeed, to our knowledge, there have been no reports by other groups of two conformers forming during synthetic cyclisations in cADPR analogue synthesis. However, in some instances cyclisation of a linear mono-thiophenyl phosphate precursor generated a cyclic dimer as the major product 29 . To try and rationalise the formation of only one conformer, in the light of the possibility of cyclisation occurring on either side of the adenine ring, we considered the linear precursor (7) to cyclisation in our intermediates that possessed an N1-sugar of the D-configuration (Fig. 7a ). The hypoxanthine base itself is aromatic and planar, and there is rotational flexibility around both ribose C-5-phosphate groups. The ribose rings are more constrained and if there is complete free rotation around bonds N1, N9 and both ribose C-5-phosphates, it is hard to conceive the formation of only one cyclic conformer. We considered whether the N1 and N9-ribose rings could exert some control over or pre-determine the locus of pyrophosphate bond formation. For a hypoxanthine precursor such as 7 (as in Fig. 6 ) we postulated that an intramolecular hydrogen bond could arise between the hypoxanthine 6 = O and the 2′-OH (Fig. 7a ). The resultant restriction on rotation around the N1-bond combined with the fixed configuration of the ribose ring may lead to a lower energy conformation with the "northern" phosphate predisposed to sit on one side of the hypoxanthine ring. Modelling of the simplified analogue, 8-Br-N1-inosine monophosphate, suggests a minimum energy conformation in which the 2′-OH is orientated towards the 6 = O, at a distance of 1.9 Å, a characteristic within the typical range for a hydrogen bond (Fig. 7b ). This predisposes the "northern" C-5-phosphate to sit to the right of the base.
In order to illustrate the idea of cyclisation on either face of the adenine and that sugar configuration could exert a directing influence on the macrocyclisation, we wanted to carry out two separate synthetic routes to generate a pair of cADPR analogue enantiomers. Such enantiomers would have identical atomic connectivity, but be trapped with their phosphate bridges on opposite sides of the base. We chose the simplified cIDPR analogue, N9-butyl-cIDPR, 8, that has only one D-ribose sugar at N1 and a simple butyl chain replacing the "southern" N9-ribose 30 . We first modelled these analogues to see if the increased flexibility afforded by the N9-butyl chain allowed interconversion of the two proposed macrocylic rings. In each case, analogues where either the "northern" or the "southern" ribose is replaced with a butyl chain still do not 'flip' from their original conformation under the standard simulation conditions. The pyrophosphate link stays on the same side of the adenine ring to the starting position (see Supplementary Information Files 14-17).
N9-butyl-cIDPR (8) has not previously been prepared via a chemo-enzymatic route. In our total synthetic route, we only observed formation of one cyclic product, prepared via 8-Br-N9-butyl-cIDPR (9) . Crystallography of the 8-NH 2 -N9-butyl-cIDPR (10) complex with human CD38 (shCD38) only captured an N1-hydrolysed product, meaning that it was not possible to determine unequivocally on what side the cyclisation had occurred 30 . However, since the "northern" D-ribose predisposed the phosphate cyclisation to occur on the right, in cIDPR, then it is most likely that the same single product (or conformer) would be generated for N9-butyl-cIDPR (i.e. phosphates on the right). This is in agreement with the N9-butyl-cIDPR analogues being substrates for CD38, and the co-crystal structure showing that CD38 can still hydrolyse 8-NH 2 -N9-butyl-cIDPR (10) 30 .
To test the idea that a linear precursor in a total synthetic route is predisposed to cyclise on one particular face, generating one of the two theoretically possible conformers, we designed a corresponding simpler and more flexible analogue with an L-configuration "northern" ribose. L-ribose, the mirror image of D-ribose, at the N1-position should exhibit the opposite lowest energy conformation to its D-ribose counterpart. Therefore if hydrogen bonding from the ribose 2″-OH to the hypoxanthine 6 = O were important, changing the configuration of the N1-ribose would predispose cyclisation to occur on the opposite face, thus generating the other enantiomer (and corresponding opposite conformer). Thus, with only one ribose sugar, cyclisation of the L-analogue to generate 8-Br-L-N9-butyl-cIDPR (11) would generate the mirror image of 8-Br-D-N9-butyl-cIDPR (9), Fig. 8 .
Synthesis of 8-Br-L-N9-butyl-cIDPR, 11. The substrate for N1-ribosylation, 8-bromohypoxanthine 12,
was prepared as previously reported 30 . Deprotonation with DBU followed by addition of tetra-acetyl-L-ribose and trimethylsilyl-triflate (TMS-OTf) 23 afforded stereo-and regioselective N1-coupling to generate only the desired N1-ribosylated product 13 in high yield. Deprotection of the three acetyl esters using methanolic ammonia generated triol 14 (Fig. 9 ).
The 2′,3′-diol was reprotected as an isopropylidene ketal to afford 15, which allowed selective introduction of the first phosphate ester to the 5′-OH by treatment with N,N-diisopropyl-di-t-butyl-phosphoramidite and 5-phenyl-1-H-tetrazole as activator, followed by oxidation of the intermediate phosphite with hydrogen peroxide and triethylamine to afford 16 (Fig. 9 ). The silyl ether of 16 was then removed under neutral conditions to reveal the hydroxyl group. The second protected phosphate ester was introduced by treatment of the resulting 17 with cyclohexylammonium S,S-diphenylphosphorodithioate (PSS), 2,4,6-triisopropylbenzenesulfonyl chloride (TPS-Cl) and 5-phenyl-1-H-tetrazole in pyridine to generate the fully protected precursor for cyclisation, 18. Sequential deprotection of the phosphates was carried out as previously described 23 using first 50% aqueous TFA to simultaneously remove the tert-butyl esters and the isopropylidene ketal, then 0.1 M sodium hydroxide in dioxane, to afford 20. Cyclization of 20 was promoted using iodine and activated 3 Å molecular sieves in pyridine 18 , under very dilute conditions, to afford the target analogue 11 (Fig. 9 ).
8-Br-L-N9-butyl-cIDPR 11 is identical by HPLC and NMR to 8-Br-D-N9-butyl-cIDPR, 9. This would be expected if cyclisation of 8-Br-L-N9-butyl-cIDPR (11) had occurred on the "left" of the base, to generate the mirror image of 8-Br-D-N9-butyl-cIDPR (9) and that each enantiomer also presents as the same mirror image conformer. For the complete avoidance of doubt we measured the optical rotation of both isomers. . Cyclisation of 20 on the "right" of the base or a mixture of products, would also be expected to result in visible differences by NMR due to the different environments of the ribose ring protons. That only one product is generated from the linear precursor in each case suggests it is predisposed towards cyclisation on a particular face. In this example, this control presumably arises from the configuration of the "northern" ribose since the N9-butyl chain would be very flexible.
We recently observed surprising differences in biological activity for other cIDPR analogues prepared for the first time with an L-ribose as the "northern" ribose 31 . Thus "L-cIDPR" is a less potent inhibitor of CD38-mediated cADPR hydrolysis than cIDPR, but was surprisingly still hydrolysed by high concentrations of CD38. On the other hand, 8-Br-L-cIDPR was a potent inhibitor of CD38-mediated cADPR hydrolysis (IC 50 = 7 µM) but was not turned over by the enzyme suggesting that it binds to CD38 in a way that is inaccessible to the catalytic machinery of the active site. Both L-ribose analogues were prepared via cyclisation of the same linear precursor and therefore must have the same conformation. While we earlier offered a robust explanation of this activity, in that the same enzymatic machinery (perhaps surprisingly) should in principle be able to cleave the new N1-L-ribose linkage, we now may have to consider the possibility that this synthetic compound has a conformation with the pyrophosphate on the left of the adenosine ring (i.e. conformer B). For these analogues, both the "northern" and "southern" ribose rings of the linear precursor may influence the location of pyrophosphate formation, relative to the adenine ring. While this consideration may not explain the differences observed between the two L-ribose analogues, it presents another possible contributing factor.
Conclusions
Our modelling suggests that under physiological conditions N1-cADPR does not flip between the two possible conformers (A and B) . Therefore, it could in principle exist as two distinct conformers. To our knowledge, this has not previously been taken into consideration during total synthetic routes to cADPR analogues that may generate either one (or both) possible products, with the concomitant implications for biological activity.
We have prepared 8-Br-cIDPR (5), using both enzyme-mediated and synthetic routes. The NMR spectrum of chemically synthesised 8-Br-cIDPR is identical to that of enzymatically synthesised material and both samples were hydrolysed by high concentrations of CD38. Taken together, this suggests that the same conformer was formed using both methods. In this case, it is perhaps fortuitous that synthetic cyclisation of the macrocycle only generates one conformer, and that a D-ribose sugar predisposes the linear compound to generate the same conformer as both the chemo-enzymatic route and the published X-ray structure of cADPR.
The first synthesis of the pair of enantiomers 8-Br-D-N9-butyl-cIDPR and 8-Br-L-N9-butyl-cIDPR reported here illustrates cyclisation on either face of the adenine. The conformational product generated may be controlled by the shape of the linear precursor.
N1-cADPR itself is more complex with both "northern" and "southern" D-ribose sugars. Based on our results, it seems likely that a N1-cADPR analogue with both L-ribose sugars prepared by total synthesis would cyclise to generate the mirror image of N1-cADPR with the corresponding single mirror image conformer. If one of the "northern" or "southern" ribose sugars was to be D-ribose and the other L-ribose it is less clear, however, what conformation the cyclised analogue would adopt, as it is possible that both ribose rings may affect the conformation of the linear precursor. These compounds have not yet all been synthesised, but the observations reported here may potentially contribute to the unexpected biological activity of some recent analogues we reported with a "northern" L-ribose 31 . Thus, an awareness of the possibility of different conformers and the potential implications for biological activity should be considered in any future cADPR analogue studies using total synthesis 19, 21, 23, [31] [32] [33] . This may however be most relevant in situations where any "northern" ribose surrogate does not possess functional groups with the ability to "lock" the cyclisation precursor onto one face, as in Fig. 7 , and thus control the direction of ring closure. Examples here would be cIDPRE, where the "northern" ribose is a totally flexible ether chain 34 , cIDPDE with both riboses so replaced 35 and those similar compounds with both ether and alkane chain surrogates 22 , including more recent N1-pentyl and corresponding phosphonopyrophosphate analogues 33 . It could well be pertinent now to re-examine the structures and activities of all such analogues in the light of this work.
Methods

Synthesis.
General. All reagents and solvents were of commercial quality and were used without further purification, unless described otherwise. Unless otherwise stated, all reactions were carried out under an inert atmosphere of argon. 1 H, 13 C, and 31 P NMR spectra were collected on a Varian Mercury 400 MHz or Bruker Avance III 500 MHz Spectrometer. All 1 H-and 13 C-NMR assignments are based on gCOSY, gHMBC, gHSQC, and DEPT-135 experiments. Abbreviations for splitting patterns are as follows: b, broad; s, singlet; d, doublet; t, triplet; m, multiplet etc. High resolution time-of-flight mass spectra were obtained on a Bruker Daltonics micrO-TOF mass spectrometer using electrospray ionisation (ESI). Optical rotations were measured as solutions in MilliQ water (pH = 7) on a Schmidt Haensch UniPol polarimeter at the sodium D line at 22 ± 1.0 °C, in a 1 cm 3 cell, and specific rotation is given in 10 −1 deg cm 3 g −1 . Analytical HPLC analyses were carried out on a Waters 2695 Alliance module equipped with a Waters 2996 Photodiode Array Detector (210-350 nm). The chromatographic system consisted of a Hichrom Guard Column for HPLC and a Phenomenex Synergi 4μ MAX-RP 80 A column (150 × 4.60 mm), eluted at 1 mL/min with the following ion-pair buffer: 0.17% (m/v) cetrimide and 45% (v/v) phosphate buffer (pH 6.4) in MeOH. Synthetic phosphates were assayed and quantified by the Ames phosphate test.
9-(4-tert-butyldiphenylsilylbutyl)-8-bromohypoxanthine (12) was prepared as previously reported 30 . (13) (14) ; N1- 
N1-(2′,3′,5′-Tri-O-acetyl-β-L-ribofuranosyl)-N9-[4-(tert-butyldiphenylsilyl)oxybutyl)-8-bromohypoxanthine
N1-(β-L-ribofuranosyl)-N9-[4-(tert-butyldiphenylsilyl)oxybutyl)-8-bromohypoxanthine
